{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T22:19:49Z","timestamp":1778969989604,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"am","delay-in-days":302,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH107183"],"award-info":[{"award-number":["R01 MH107183"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jad.2022.07.054","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T12:47:24Z","timestamp":1658839644000},"page":"13-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder"],"prefix":"10.1016","volume":"315","author":[{"given":"Kelly S.","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2022.07.054_bb0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpsychires.2014.07.027","article-title":"Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety","volume":"58","author":"Ballard","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2022.07.054_bb0010","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of Beck depression inventories-IA and -II in psychiatric outpatients","volume":"67","author":"Beck","year":"1996","journal-title":"J. Pers.Assess."},{"key":"10.1016\/j.jad.2022.07.054_bb0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol.Psychiatry"},{"key":"10.1016\/j.jad.2022.07.054_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J. Trauma. Stress."},{"key":"10.1016\/j.jad.2022.07.054_bb0025","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.jad.2022.07.054_bb0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jad.2020.11.111","article-title":"How does borderline personality disorder affect management and treatment response of patients with major depressive disorder? A comprehensive review","volume":"281","author":"Ceresa","year":"2021","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.jad.2022.07.054_bb0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to Oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2022.07.054_bb0040","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder","volume":"71","author":"DiazGranados","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2022.07.054_bb0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jad.2022.07.054_bb0050","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1521\/pedi.15.6.536.19187","article-title":"The factor structure of the personality assessment inventory-borderline features (PAI-BOR) scale in a nonclinical sample","volume":"15","author":"Jackson","year":"2001","journal-title":"J. Personal. Disord."},{"key":"10.1016\/j.jad.2022.07.054_bb0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1521\/pedi.2000.14.4.316","article-title":"Recent life events, social adjustment, and suicide attempts in patients with major depression and borderline personality disorder","volume":"14","author":"Kelly","year":"2000","journal-title":"J. Personal. Disord."},{"key":"10.1016\/j.jad.2022.07.054_bb0060","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.brat.2013.04.008","article-title":"Effectiveness, response, and dropout of dialectical behavior therapy for borderline personality disorder in an inpatient setting","volume":"51","author":"Kr\u00f6ger","year":"2013","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.jad.2022.07.054_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11599770-000000000-00000","article-title":"Ketamine for treatment-resistant unipolar depression: current evidence","volume":"26","author":"Mathew","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2022.07.054_bb0070","series-title":"The Personality Assessment Inventory Professional Manual","author":"Morey","year":"2007"},{"key":"10.1016\/j.jad.2022.07.054_bb0075","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2022.07.054_bb0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/08039480500320025","article-title":"Suicide in borderline personality disorder: a meta-analysis","volume":"59","author":"Pompili","year":"2005","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.jad.2022.07.054_bb0085","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/da.22253","article-title":"Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression","volume":"31","author":"Price","year":"2014","journal-title":"Depress Anxiety."},{"key":"10.1016\/j.jad.2022.07.054_bb0090","series-title":"Borderline Personality Disorder: Towards Effective Treatment","first-page":"87","article-title":"Biological treatments.","author":"Rao","year":"2010"},{"issue":"Suppl. 20","key":"10.1016\/j.jad.2022.07.054_bb0095","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2022.07.054_bb0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2017","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jad.2022.07.054_bb0105","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1176\/ajp.155.12.1733","article-title":"Axis I comorbidity of borderline personality disorder","volume":"155","author":"Zanarini","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2022.07.054_bb0110","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2022.07.054_bb0115","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.psychres.2015.01.020","article-title":"Assessing the contribution of borderline personality disorder and features to suicide risk in psychiatric inpatients with bipolar disorder, major depression and schizoaffective disorder","volume":"226","author":"Zeng","year":"2015","journal-title":"Psychiatry Res."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032722008229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032722008229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T03:17:44Z","timestamp":1759029464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032722008229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":23,"alternative-id":["S0165032722008229"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2022.07.054","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of IV ketamine in patients with major depressive disorder and elevated features of borderline personality disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2022.07.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}